tiprankstipranks
Trending News
More News >
OncoSil Medical Ltd (AU:OSL)
:OSL
Australian Market

OncoSil Medical Ltd (OSL) AI Stock Analysis

Compare
13 Followers

Top Page

AU

OncoSil Medical Ltd

(Sydney:OSL)

Rating:35Underperform
Price Target:
OncoSil Medical Ltd's stock faces significant challenges with poor financial performance, characterized by declining revenues and persistent losses, which are major concerns for long-term viability. The lack of technical analysis data and a negative P/E ratio further emphasize the risks. The absence of dividend yield also detracts from the stock's attractiveness. Overall, these factors result in a low stock score.

OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)

OncoSil Medical Ltd Business Overview & Revenue Model

Company DescriptionOncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
How the Company Makes MoneyOncoSil Medical Ltd generates revenue primarily through the sale and distribution of its OncoSil device to healthcare providers, hospitals, and cancer treatment centers. The company seeks to expand its market presence by securing regulatory approvals across various regions, which enables commercialization and wider adoption of its technology. Key revenue streams come from direct sales, potential licensing agreements, and partnerships with medical institutions that facilitate the integration of the OncoSil device into existing cancer treatment protocols. Additionally, the company may benefit from research grants and funding opportunities that support the development and clinical trials of its products.

OncoSil Medical Ltd Financial Statement Overview

Summary
OncoSil Medical Ltd faces significant financial challenges with declining revenues, consistent losses, and negative cash flows, raising concerns about its long-term viability. While the company benefits from low debt levels, the ongoing lack of profitability and cash generation is troubling.
Income Statement
20
Very Negative
OncoSil Medical Ltd has experienced declining revenues and significant losses over the years. The revenue growth rate is negative, indicating shrinking top-line performance. Gross profit margins are extremely low, and the company has consistently reported negative net profit and EBIT margins, highlighting ongoing profitability challenges.
Balance Sheet
30
Negative
The company maintains a relatively low debt-to-equity ratio, suggesting limited leverage, which is a positive aspect. However, the return on equity is negative due to consistent net losses, indicating poor returns for shareholders. The equity ratio is moderate, suggesting some financial stability through equity financing.
Cash Flow
25
Negative
Cash flow analysis reveals persistent negative free cash flow, indicating operational cash outflows exceed incoming cash. The operating cash flow to net income ratio is unstable due to ongoing losses. This poses a sustainability risk if the trend continues without improvement.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
1.41M516.63K367.68K231.79K213.07K2.76M
Gross Profit
-2.42M-993.12K-6.49M-6.73M-6.23M2.61M
EBIT
-13.09M-11.98M-12.55M-11.41M-11.63M-7.21M
EBITDA
-13.06M-11.98M-11.32M-11.41M-10.51M-6.87M
Net Income Common Stockholders
-13.07M-11.91M-11.34M-10.73M-10.43M-4.26M
Balance SheetCash, Cash Equivalents and Short-Term Investments
13.04M4.50M9.39M11.28M12.24M21.00M
Total Assets
15.29M6.72M11.47M13.07M14.15M24.06M
Total Debt
60.45K70.67K170.81K304.21K484.37K109.94K
Net Debt
-12.98M-4.43M-9.22M-10.98M-11.76M-20.89M
Total Liabilities
1.79M1.98M1.59M1.91M2.45M2.16M
Stockholders Equity
13.51M4.74M9.88M11.16M11.70M21.90M
Cash FlowFree Cash Flow
-12.84M-11.02M-11.37M-10.12M-8.87M-4.48M
Operating Cash Flow
-12.63M-10.82M-11.32M-10.11M-8.82M-4.46M
Investing Cash Flow
-208.41K-197.06K-57.82K-5.83K-54.00K-20.72K
Financing Cash Flow
16.40M6.13M9.49M9.16M111.25K17.79M

OncoSil Medical Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
AUOSL
35
Underperform
AU$11.29M-199.38%271.05%42.55%
$2.16M-119.28%
$77.69M-99.05%
AURAC
54
Neutral
AU$205.88M-37.20%32.02%
AUPYC
53
Neutral
AU$702.83M-112.97%-84.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:OSL
OncoSil Medical Ltd
0.98
-3.42
-77.73%
BITRF
Biotron Limited
0.05
0.02
66.67%
IUGNF
Imugene Limited
0.01
-0.03
-75.00%
AU:PYC
PYC Therapeutics Limited
1.20
0.16
15.38%
AU:RAC
Race Oncology Ltd.
1.17
-0.73
-38.42%

OncoSil Medical Ltd Corporate Events

OncoSil Medical Ltd Announces Extraordinary General Meeting
Jun 5, 2025

OncoSil Medical Ltd has announced an Extraordinary General Meeting (EGM) scheduled for July 8, 2025, in Melbourne. This meeting is crucial for shareholders as it impacts their holdings, and they are encouraged to vote either in person or by proxy. The meeting will address significant business matters, and shareholders are advised to seek professional guidance if unsure about their voting decisions. This EGM could have implications for the company’s strategic direction and stakeholder interests.

OncoSil Medical Completes Capital Consolidation to Strengthen Market Position
Jun 5, 2025

OncoSil Medical Limited has completed a capital consolidation on a 1 for 400 basis, as approved by shareholders, to streamline its capital structure. This move is part of the company’s strategy to enhance its market position as it continues to commercialize its innovative cancer treatment technology. The consolidation is expected to impact trading, with normal trading on a post-consolidation basis set to commence on June 13, 2025.

OncoSil Medical Ltd Launches Security Purchase Plan for Shareholders
Jun 4, 2025

OncoSil Medical Ltd has announced the opening of a Security Purchase Plan (SPP) for eligible shareholders, primarily in Australia and New Zealand. This plan allows shareholders to purchase up to $100,000 of new fully paid OncoSil ordinary shares without incurring brokerage or transaction costs. The offer includes one free attaching option for every new share issued, with the options having an exercise price of $0.003 each and an expiry date of July 31, 2027. The SPP aims to strengthen OncoSil’s financial position as it continues to commercialize its innovative cancer treatment technology.

OncoSil Medical Ltd Issues Over 1 Billion Shares to Bolster Capital
Jun 3, 2025

OncoSil Medical Ltd has announced the issuance of over 1 billion ordinary shares without disclosure under the Corporations Act, in compliance with relevant legal provisions. This move reflects the company’s strategic financial maneuvers to potentially enhance its capital structure, which could influence its market position and stakeholder interests.

OncoSil Medical Announces Shareholder-Approved Security Consolidation
May 29, 2025

OncoSil Medical Ltd has announced a consolidation of its securities, which was approved by shareholders at an Extraordinary General Meeting on May 29, 2025. This reorganization affects various securities, including ordinary shares and options with different expiration dates, and is part of the company’s strategic efforts to streamline its capital structure and potentially enhance shareholder value.

OncoSil Medical Ltd Successfully Passes Key Resolutions at Extraordinary General Meeting
May 29, 2025

OncoSil Medical Ltd announced that all resolutions at their Extraordinary General Meeting were carried by poll. This includes the approval of share consolidation, future issue of shares, an omnibus plan, and the issuance and ratification of options. The successful passing of these resolutions is expected to impact the company’s operational strategies and potentially enhance its market position, benefiting stakeholders by aligning with its growth objectives.

OncoSil Medical Ltd Announces Proposed Securities Issue
May 26, 2025

OncoSil Medical Ltd has announced a proposed issue of securities under a securities purchase plan, aiming to issue a total of 666,666,667 new securities. This move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing its capital base, which may be used for further development and expansion activities.

OncoSil Medical Ltd Announces Proposed Securities Issuance
May 26, 2025

OncoSil Medical Ltd has announced a proposed issuance of securities, including options and ordinary shares, set to take place on July 11, 2025. This move is part of a strategic effort to raise capital, potentially enhancing the company’s financial position and supporting its ongoing operations and growth initiatives within the oncology sector.

OncoSil Medical Ltd Announces Capital Raise and Future Prospects
May 26, 2025

OncoSil Medical Ltd has released a presentation regarding a capital raise, emphasizing that the information provided is not an offer for securities but rather a general overview of the company’s operations and future prospects. The presentation includes forward-looking statements about the company’s product candidates and their potential regulatory approvals, highlighting the risks and uncertainties involved. Stakeholders are advised to seek independent advice due to the speculative nature of the information presented.

OncoSil Medical Ltd Launches $8.7 Million Capital Raising Initiative
May 26, 2025

OncoSil Medical Ltd has announced a Share Purchase Plan and Placement to raise approximately $8.7 million before offer costs, subject to shareholder approval. The capital raising initiative includes offering new shares and options to eligible shareholders and invited investors, with Bell Potter appointed as the Lead Manager. This move is expected to bolster the company’s financial position and support its ongoing operations and strategic initiatives in the medical device industry.

OncoSil Medical Secures $8.7M for Pancreatic Cancer Device Expansion
May 26, 2025

OncoSil Medical Ltd has announced an $8.7 million capital raise to accelerate the commercialization of its pancreatic cancer treatment device. The funds will support ongoing clinical trials and commercialization efforts, with a focus on expanding market access in Europe and existing jurisdictions. The capital raise includes a placement and a Share Purchase Plan (SPP), with strong backing from institutional investors, including Pengana High Conviction Equities Fund. The completion of two major clinical trials, PANCOsil and TRIPP-FFX, is expected to significantly enhance the company’s market access and operational cash flow by the second half of 2026.

OncoSil Medical Ltd Initiates Trading Halt Ahead of Capital Raise Announcement
May 21, 2025

OncoSil Medical Ltd has requested a trading halt on its securities pending an announcement related to a capital raise. This move indicates a potential strategic financial maneuver that could impact the company’s operations and market positioning, with implications for investors and stakeholders as they await further details.

OncoSil Medical’s Device Outperforms SBRT in Pancreatic Cancer Treatment
May 6, 2025

OncoSil Medical Limited announced the results of a comparative analysis demonstrating the superiority of its OncoSil™ device over Stereotactic Body Radiation Therapy (SBRT) in treating locally advanced pancreatic cancer. The study showed that OncoSil™ significantly extends overall survival and progression-free survival compared to SBRT, with a higher rate of downstaging and surgical resection. These findings, presented at the Digestive Disease Week 2025, highlight the potential of OncoSil™ in treating earlier stages of pancreatic cancer and reinforce its efficacy and safety when added to standard chemotherapy. This development marks a significant milestone for OncoSil Medical, enhancing its positioning in the cancer treatment industry.

OncoSil Medical Ltd Announces Quotation of New Securities on ASX
May 5, 2025

OncoSil Medical Ltd has announced the quotation of 2,076 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 5, 2025. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase liquidity, reflecting its ongoing commitment to growth and value creation for its stakeholders.

OncoSil Medical Reports Record Growth in Q3 FY25
May 2, 2025

OncoSil Medical Ltd reported record quarterly dose sales for Q3 FY25, driven by increased clinical adoption of the OncoSil™ device. The company saw a 233% increase in dose sales compared to the previous year, contributing to an 83% rise in year-to-date sales and a 135% increase in year-to-date revenues. This growth highlights the company’s successful market penetration and strategic advancements, including receiving MDR approval and expanding its presence in German hospitals. The financial results indicate a promising outlook for future revenue growth as sales figures are expected to be more fully realized in upcoming quarters.

OncoSil Medical Ltd Updates Security Consolidation Announcement
May 1, 2025

OncoSil Medical Ltd has announced an update to its previous notification regarding the consolidation or split of its securities, specifically including the OSLOC option expiring on December 20, 2027. This update signifies a strategic move in managing its financial instruments, potentially impacting stakeholders by altering the structure of investment opportunities within the company.

OncoSil Medical Announces Security Consolidation
May 1, 2025

OncoSil Medical Ltd has announced a security consolidation, affecting various securities including ordinary shares and options with different expiration dates. This reorganization is set to commence trading on a deferred settlement basis from June 3, 2025, with a record date of June 4, 2025, and an issue date of June 12, 2025. The consolidation is part of the company’s strategic efforts to streamline its securities structure, which could impact its market positioning and provide clarity for stakeholders.

OncoSil Medical Advances in German Market with New Study Tender
Apr 30, 2025

OncoSil Medical Limited has announced that the Federal Joint Committee in Germany has initiated a tender process to select a Contract Research Organisation for a study on the OncoSil™ device. This study will evaluate the device’s effectiveness in combination with chemotherapy for treating unresectable, locally advanced pancreatic cancer. This development is a significant step towards potential inclusion in German treatment guidelines and the statutory health insurance system, which could impact the company’s market positioning and stakeholder interests.

OncoSil Medical Ltd Announces Extraordinary General Meeting for Shareholders
Apr 30, 2025

OncoSil Medical Ltd has announced an Extraordinary General Meeting (EGM) scheduled for May 29, 2025, in Carlton, Victoria. This meeting is significant for shareholders as it will address matters affecting their shareholding, and they are encouraged to participate either in person or by proxy. The announcement underscores the importance of shareholder involvement in the company’s decision-making processes, potentially impacting its strategic direction and market positioning.

OncoSil Medical Reports Record Growth and Strategic Advancements in Q3 FY25
Apr 29, 2025

OncoSil Medical Ltd reported record quarterly dose sales in Q3 FY25, reflecting a 233% increase compared to the previous year, driven by the growing clinical adoption of the OncoSil™ device. The company also received a $1.05 million R&D tax incentive and made strategic appointments and advancements, including the addition of Ms. Lel Smits to the Board of Directors and Ms. Shelley Steyn as CFO. Advisory Board meetings in the UK and Germany outlined strategic pathways for the device’s advancement, aiming to strengthen OncoSil’s position in the healthcare systems of these regions.

OncoSil Medical Appoints New Company Secretary Amid Global Expansion
Mar 31, 2025

OncoSil Medical Limited has appointed Nathan Jong as the new Company Secretary, succeeding Christian Dal Cin. Nathan Jong, with his extensive experience in corporate secretarial and finance roles within the life sciences sector, will handle communication with the ASX regarding listing rule matters. This appointment is expected to strengthen OncoSil’s operational framework as it continues to commercialize its innovative pancreatic cancer treatment device globally.

OncoSil Medical Appoints New CFO Amid Strategic Growth Phase
Mar 17, 2025

OncoSil Medical Limited has appointed Ms. Shelley Steyn as Chief Financial Officer, effective May 5, 2025, as part of its strategy to strengthen leadership during a critical development phase. Ms. Steyn’s extensive experience in financial roles is expected to enhance OncoSil’s strategic priorities, improve financial control, and support the company’s efforts in closing clinical trial recruitments and resubmitting a marketing authorization application to the Therapeutics Goods Association.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.